Atria Investments Inc Has $1.79 Million Stock Holdings in DexCom, Inc. $DXCM

Atria Investments Inc lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 12.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,530 shares of the medical device company’s stock after buying an additional 2,202 shares during the period. Atria Investments Inc’s holdings in DexCom were worth $1,792,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Zions Bancorporation National Association UT acquired a new position in shares of DexCom during the 1st quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of DexCom during the 2nd quarter worth about $45,000. Anderson Financial Strategies LLC acquired a new position in shares of DexCom during the 1st quarter worth about $37,000. Private Trust Co. NA boosted its stake in shares of DexCom by 99.4% during the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after buying an additional 335 shares during the last quarter. Finally, Ameritas Advisory Services LLC acquired a new position in shares of DexCom during the 2nd quarter worth about $84,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Up 1.2%

DexCom stock opened at $61.18 on Wednesday. The stock has a market cap of $23.99 billion, a P/E ratio of 42.49, a P/E/G ratio of 1.43 and a beta of 1.47. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a twelve month low of $56.44 and a twelve month high of $93.25. The company’s 50-day moving average price is $70.33 and its two-hundred day moving average price is $77.91.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.04. The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business’s revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. The trade was a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares of the company’s stock, valued at approximately $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 5,383 shares of company stock valued at $434,274 in the last 90 days. Insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on DXCM. TD Cowen reduced their price objective on shares of DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research note on Friday, October 31st. UBS Group cut their target price on shares of DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research note on Monday. Oppenheimer downgraded shares of DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of DexCom in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 10th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $89.33.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.